These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 16750471)

  • 1. Double counting and the reporting of cost per event avoided.
    Mullins CD
    Clin Ther; 2006 Apr; 28(4):602-3. PubMed ID: 16750471
    [No Abstract]   [Full Text] [Related]  

  • 2. Quality-adjusted life-years as decisionmaker tools to address limitations inherent in number-needed-to-treat/harm values.
    Raisch DW; Nawarskas JJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):99-102. PubMed ID: 19402794
    [No Abstract]   [Full Text] [Related]  

  • 3. What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation.
    Mullahy J
    Med Care; 1996 Dec; 34(12 Suppl):DS124-35. PubMed ID: 8969321
    [No Abstract]   [Full Text] [Related]  

  • 4. How can pharmacoeconomics be more useful?
    Kozma CM
    Manag Care Interface; 2005 May; 18(5):25-6. PubMed ID: 15941186
    [No Abstract]   [Full Text] [Related]  

  • 5. Statistical comments.
    Kikushi T
    Value Health; 2008; 11(2):345; discussion 346. PubMed ID: 18380647
    [No Abstract]   [Full Text] [Related]  

  • 6. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
    von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Where does high-quality research in economic evaluation come from?
    Zhang JX
    Pharmacotherapy; 2009 Jan; 29(1):1-2. PubMed ID: 19113791
    [No Abstract]   [Full Text] [Related]  

  • 8. Discounting health effects in pharmacoeconomic evaluations: current controversies.
    Birks S
    Pharmacoeconomics; 2006; 24(12):1273-4; author reply 1275-6. PubMed ID: 17129079
    [No Abstract]   [Full Text] [Related]  

  • 9. [What is a cost-benefit analysis?].
    Müller-Bohn T
    Med Monatsschr Pharm; 2004 Oct; 27(10):328-30. PubMed ID: 15527174
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness as an outcome in randomized clinical trials.
    Hlatky MA; Owens DK; Sanders GD
    Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

  • 12. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The power of pharmacoeconomics.
    Healthc Exec; 2000; 15(1):44-5. PubMed ID: 11067028
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analyses alongside randomised clinical trials.
    Gray AM
    Clin Trials; 2006; 3(6):538-42. PubMed ID: 17170038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
    Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
    Cancer; 2008 Mar; 112(5):1058-65. PubMed ID: 18186497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redefining the analytical approach to pharmacoeconomics.
    Luce BR; Claxton K
    Health Econ; 1999 May; 8(3):187-9. PubMed ID: 10348413
    [No Abstract]   [Full Text] [Related]  

  • 18. Avoiding double-counting in pharmacoeconomic studies.
    Johannesson M
    Pharmacoeconomics; 1997 May; 11(5):385-8. PubMed ID: 10168027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What affects the quality of economic analysis for life-saving investments?
    Hahn RW; Kosec K; Neumann PJ; Wallsten S
    Risk Anal; 2006 Jun; 26(3):641-55. PubMed ID: 16834624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.